Gastroesophageal Cancer | Disease Landscape & Forecast | G7 | 2024
The advent of Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) has revolutionized the treatment of gastroesophageal cancer, leading to substantial growth of this indication’s drug therapy market. The expected approval of novel immune checkpoint inhibitors will further reshape the HER2-negative gastroesophageal cancer therapy. Multimodal therapy consisting of HER2-targeted agents, immune checkpoint inhibitors, and chemotherapy has expanded therapeutic options for HER2-positive disease. We expect the gastroesophageal cancer therapy landscape to gain additional complexity as novel biomarker-specific therapies (claudin 18.2 inhibitors and FGFR2b inhibitors) expand the range of available treatments. Given the significant progress in the late-phase pipeline, we expect the approval of several new therapies for gastroesophageal cancer during the forecast period.
Questions answered
- How is gastroesophageal cancer segmented by subpopulation, and what is the size of the drug-treatable and drug-treated populations?
- What are the key current therapies for gastroesophageal cancer, and how are they positioned in the treatment algorithm?
- Which emerging therapies are the most promising, and how will they shape the future of the gastroesophageal cancer therapy market?
- What are the drivers of and constraints on the gastroesophageal cancer therapy market, and how will the market evolve over the forecast period?
Content highlights
Geographies: United States, EU5, Japan
Primary research: 19 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed and recurrent incidence of gastroesophageal cancer by country, segmented by stage of disease, histology, HER2 status, and line of therapy
Forecast: 10-year, annualized, drug-level sales and patient share of key gastroesophageal cancer therapies through 2033, segmented by brands / generics / biosimilars and drug-treatable populations
Drug treatments: Coverage of key current and emerging therapies
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
